Adjuvant battleground steps back into ASCO spotlight
Late-breaking abstracts at ASCO21 highlight progress in untapped adjuvant setting markets
Late-breaking abstracts at ASCO21 highlight progress in untapped adjuvant setting markets.
It’s all about adjuvant indications and their untapped market potential leading into ASCO21 as the early line of treatment comes into reach for checkpoint inhibitors and selective targeted therapies with new data presented at the conference.
Six late-breaking abstracts were released on the eve of the American Society of Clinical Oncology (ASCO) conference, two of which describe highly anticipated pivotal readouts for the adjuvant line of treatment.
Merck & Co. Inc. (NYSE:MRK) will present the first Phase III survival benefit for adjuvant treatment of renal cell carcinoma (RCC); the data come from the KEYNOTE-564 study of its blockbuster PD-1 inhibitor Keytruda pembrolizumab.
Merck and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) will also present results from the Phase III OlympiA study that makes Lynparza olaparib the first PARP inhibitor to show clinical value as an adjuvant treatment